End stage heart failure
Methodology & AI Transparency ⓘ
End stage heart failure Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: End stage heart failure—coded clinically as I50.84 across Heart & Vascular guidelines—combines ambulatory rhythm monitoring [End stage heart failure I50.84] with structured follow-up of Apolipoprotein B (ApoB) [End stage heart failure I50.84] (< 70 mg/dL (I50.84)).
- 2 Real-world patient consensus: Diagnostic registry I50.84: End stage heart failure is managed within Heart & Vascular.
- 3 Typical cash cost range: Workup highlights for End stage heart failure (I50.84): ambulatory rhythm monitoring [End stage heart failure I50.84].
- 4 Top reported side effects / signs: Longitudinal End stage heart failure monitoring tracks High-Sensitivity Troponin I [End stage heart failure I50.84] toward < 14 ng/L (I50.84).
Ask our AI Specialists anything about End stage heart failure
What Is End stage heart failure?
End stage heart failure—coded clinically as I50.84 across Heart & Vascular guidelines—combines ambulatory rhythm monitoring [End stage heart failure I50.84] with structured follow-up of Apolipoprotein B (ApoB) [End stage heart failure I50.84] (< 70 mg/dL (I50.84)).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of End stage heart failure (I50.84) center on structural ventricular wall in End stage heart failure (I50.84: stress). targeted heart & vascular interventions aim to normalize High-Sensitivity Troponin I [End stage heart failure I50.84].
Common Symptoms & Clinical Signs
- • Presentation of End stage heart failure (I50.84): exertional chest pressure in End stage heart failure (I50.84: or retrosternal tightness)
- • Secondary End stage heart failure clinical sign: shortness of breath in End stage heart failure (I50.84: when climbing stairs)
- • Symptom flares in End stage heart failure correlating with High-Sensitivity Troponin I [End stage heart failure I50.84] deviation outside < 14 ng/L (I50.84)
- • Functional heart & vascular impact requiring ambulatory rhythm monitoring [End stage heart failure I50.84] evaluation (I50.84)
End stage heart failure Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I50.84 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [End stage heart failure I50.84] | < 14 ng/L (I50.84) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [End stage heart failure I50.84] | < 70 mg/dL (I50.84) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Left Ventricular Ejection in End stage heart failure (I50.84: Fraction (LVEF)) | 55% – 70% (I50.84) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for End stage heart failure
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Lanthanum Carbonate Fosrenol • RxCUI 477347 | Phosphate Binder | 75% | $2.8768 | $ 35.08 /mo |
| Oxaliplatin Oxaliplatin Generic • RxCUI 1736776 | Platinum-based Drug | 86% | $3.3800 | $ 145.39 /mo |
| Brentuximab Vedotin Adcetris • RxCUI 1147323 | CD30-directed Immunoconjugate | 87% | $1.6600 | $ 75.73 /mo |
| Petitcochon Tone Up Body Sun (Adenosine, Niacinamide) Petitcochon Tone Up Body Sun • RxCUI RXN-B820830022 | Adenosine Receptor Agonist | 83% | $2.0100 | $ 153.22 /mo |
| Fexinidazole Fexinidazole Generic • RxCUI 2564151 | Nitroimidazole Antimicrobial | 82% | $0.1800 | $ 15.79 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (End stage heart failure)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Continuum of renoprotection with losartan at all stages of type 2 diabetic: What a 1,513-Participant Study Found In proteinuric individuals with type 2 diabetes, losartan therapy reduced ESRD and hospitalizations for heart failure and was well tolerated at all levels of kidney function. Journal of the American Society of Nephrology : JASN • 2004-12-15 • Randomized Controlled Trial | N = 1,513 | 96/100 | PMID 15579515 ↗ |
| New Insights on Effect of concomitant statin treatment in postmenopausal patients with hormone: What a 3,420-Participant Study Found According to this analysis, hydrophilic statins showed a detrimental effect on DFS in the main model, which was attenuated after correction for confounders. ESMO open • 2022-04-15 • Phase III Randomized Trial | N = 3,420 | 96/100 | PMID 35334418 ↗ |
| New Insights on Telmisartan and amlodipine in combination on ambulatory blood pressure in stages: What a 562-Participant Study Found These findings show that telmisartan and amlodipine in combination provide substantial 24-h BP efficacy that is superior to either single-drug treatment in patients with stages 1 and 2 high blood pressure. Blood pressure monitoring • 2010-08-15 • Randomized Controlled Trial | N = 562 | 93/100 | PMID 20613496 ↗ |
| New Insights on Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic: What a 917-Participant Study Found Results among patients with F2 and F3 fibrosis were consistent with the primary MAESTRO-NASH analysis population, demonstrating real-world benefits and safety of resmetirom after 52 weeks. Alimentary pharmacology & therapeutics • 2026-10-15 • Phase III Randomized Trial | N = 917 | 93/100 | PMID 42527732 ↗ |
| New Insights on Semaglutide in obesity-related heart failure with preserved ejection fraction: What a 573-Participant Study Found In patients with HFpEF enrolled across the STEP-HFpEF and STEP-HFpEF DM trials, treatment with semaglutide improved disease-specific symptoms, physical function and reduced body weight across the age spectrum. European journal of heart failure • 2025-11-15 • Randomized Controlled Trial | N = 573 | 93/100 | PMID 41290376 ↗ |
End stage heart failure Patient Community & “People Like Me” Threads
Filter End stage heart failure community threads and patient logs by age, biological sex, dosage, and treatment duration.